Novonesis (Novozymes) B (NVZMF)
OTC
Closed
Aug 21, 2026
Day's Range
69.7052 wk Range
52.10Overview - NVZMF - Novonesis (Novozymes) B
Key Statistics
Valuation
Enterprise Value
41.34B
P/E (Trailing)
‪43.83‬
P/E (Forward)
‪37.88‬
PEG Ratio
‪-2.32‬
Price / Sales (TTM)
‪7.56‬
Price / Book
‪2.49‬
EV / EBITDA
‪21.95‬
Profitability
Gross Margin
‪56.70%‬
Profit Margin
‪14.69%‬
Operating Margin
‪23.43%‬
Return on Assets
‪3.78%‬
Return on Equity
‪5.76%‬
Ownership
Shares Outstanding
466.22M
Float
347.61M
Held by Insiders
‪15.80%‬
Held by Institutions
‪36.32%‬
Price stats
Beta
‪0.62‬
50-Day Avg
‪63.19‬
200-Day Avg
‪60.91‬
Dividends
Payout Ratio
‪63.98%‬
Frequency
Annual
Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - NVZMF - Novonesis (Novozymes) B
Peers - NVZMF - Novonesis (Novozymes) B
Peer Comparison
Compared with companies in Specialty Chemicals listed on OTC.
Profile Summary - NVZMF - Novonesis (Novozymes) B
About
Novonesis (Novozymes) B is the Class B share of Novonesis A/S, a leading biotechnology company headquartered in Lyngby, Denmark. Formed in 2024 through the merger of Novozymes and Chr. Hansen, it holds a dominant near-50% market share in industrial enzymes and microbial solutions worldwide. The company develops and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
